386 related articles for article (PubMed ID: 16834758)
1. A new look at the 5alpha-reductase inhibitor finasteride.
Finn DA; Beadles-Bohling AS; Beckley EH; Ford MM; Gililland KR; Gorin-Meyer RE; Wiren KM
CNS Drug Rev; 2006; 12(1):53-76. PubMed ID: 16834758
[TBL] [Abstract][Full Text] [Related]
2. Finasteride treatment and neuroactive steroid formation.
Dusková M; Hill M; Hanus M; Matousková M; Stárka L
Prague Med Rep; 2009; 110(3):222-30. PubMed ID: 19655698
[TBL] [Abstract][Full Text] [Related]
3. Finasteride in the treatment of alopecia.
Libecco JF; Bergfeld WF
Expert Opin Pharmacother; 2004 Apr; 5(4):933-40. PubMed ID: 15102575
[TBL] [Abstract][Full Text] [Related]
4. The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids.
Dušková M; Hill M; Stárka L
Horm Mol Biol Clin Investig; 2010 Jan; 1(2):95-102. PubMed ID: 25961975
[TBL] [Abstract][Full Text] [Related]
5. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
[TBL] [Abstract][Full Text] [Related]
6. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
9. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma.
Caruso D; Abbiati F; Giatti S; Romano S; Fusco L; Cavaletti G; Melcangi RC
J Steroid Biochem Mol Biol; 2015 Feb; 146():74-9. PubMed ID: 24717976
[TBL] [Abstract][Full Text] [Related]
10. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss).
Shapiro J; Kaufman KD
J Investig Dermatol Symp Proc; 2003 Jun; 8(1):20-3. PubMed ID: 12894990
[TBL] [Abstract][Full Text] [Related]
11. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
12. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
13. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
15. Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice.
Kokate TG; Banks MK; Magee T; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1999 Feb; 288(2):679-84. PubMed ID: 9918575
[TBL] [Abstract][Full Text] [Related]
16. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
17. Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia.
Kaufman KD; Dawber RP
Expert Opin Investig Drugs; 1999 Apr; 8(4):403-15. PubMed ID: 15992088
[TBL] [Abstract][Full Text] [Related]
18. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility.
Reddy DS; Rogawski MA
J Neurosci; 2002 May; 22(9):3795-805. PubMed ID: 11978855
[TBL] [Abstract][Full Text] [Related]
19. Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and Their Receptors in the Male Rat Brain.
Giatti S; Foglio B; Romano S; Pesaresi M; Panzica G; Garcia-Segura LM; Caruso D; Melcangi RC
Neuroendocrinology; 2016; 103(6):746-57. PubMed ID: 26646518
[TBL] [Abstract][Full Text] [Related]
20. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.
Melcangi RC; Santi D; Spezzano R; Grimoldi M; Tabacchi T; Fusco ML; Diviccaro S; Giatti S; Carrà G; Caruso D; Simoni M; Cavaletti G
J Steroid Biochem Mol Biol; 2017 Jul; 171():229-235. PubMed ID: 28408350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
